Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis

Thirty-eight patients with virologically proven dendritic keratitis were treated using either debridement plus human leukocyte interferon (HLI) or debridement plus human fibroblast interferon (HFI) in a randomized, double-blind study. We administered one drop of HLI or HFI (1 X 10(6) reference units/ml) daily and found no significant difference in the action of either type of interferon.